BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29363499)

  • 1. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2
    Xie C; Gao X; Sun D; Zhang Y; Krausz KW; Qin X; Gonzalez FJ
    Drug Metab Dispos; 2018 Apr; 46(4):336-345. PubMed ID: 29363499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
    Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
    Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
    Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-[(1
    Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
    J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro drug metabolism of green tea catechins in human, monkey, dog, rat and mouse hepatocytes.
    Chen WW; Qin GY; Zhang T; Feng WY
    Drug Metab Lett; 2012 Jun; 6(2):73-93. PubMed ID: 22594564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism.
    Wu WN; McKown LA; Reitz AB
    Eur J Drug Metab Pharmacokinet; 2006; 31(4):277-83. PubMed ID: 17315539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite.
    Mahajan MK; Uttamsingh V; Daniels JS; Gan LS; LeDuc BW; Williams DA
    Drug Metab Dispos; 2011 Apr; 39(4):693-702. PubMed ID: 21177487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
    Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM
    J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
    Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
    Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel metabolic pathways of pioglitazone in hepatocytes: N-glucuronidation of thiazolidinedione ring and sequential ring-opening pathway.
    Uchiyama M; Fischer T; Mueller J; Oguchi M; Yamamura N; Koda H; Iwabuchi H; Izumi T
    Drug Metab Dispos; 2010 Jun; 38(6):946-56. PubMed ID: 20185540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'- (methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- 1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR.
    Mutlib AE; Shockcor J; Chen SY; Espina RJ; Pinto DJ; Orwat MJ; Prakash SR; Gan LS
    Chem Res Toxicol; 2002 Jan; 15(1):48-62. PubMed ID: 11800597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control.
    Cheng X; Prange-Barczynska M; Fielding JW; Zhang M; Burrell AL; Lima JD; Eckardt L; Argles I; Pugh CW; Buckler KJ; Robbins PA; Hodson EJ; Bruick RK; Collinson LM; Rastinejad F; Bishop T; Ratcliffe PJ
    J Clin Invest; 2020 May; 130(5):2237-2251. PubMed ID: 31999648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hypoxia impairs skeletal muscle repair via HIF-2α stabilization.
    Yin A; Fu W; Elengickal A; Kim J; Liu Y; Bigot A; Mamchaoui K; Call JA; Yin H
    J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):631-645. PubMed ID: 38333911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-targeted metabolomics-guided sildenafil metabolism study in human liver microsomes.
    Kim JH; Jo JH; Seo KA; Hwang H; Lee HS; Lee S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():86-93. PubMed ID: 29136555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
    Wallace EM; Rizzi JP; Han G; Wehn PM; Cao Z; Du X; Cheng T; Czerwinski RM; Dixon DD; Goggin BS; Grina JA; Halfmann MM; Maddie MA; Olive SR; Schlachter ST; Tan H; Wang B; Wang K; Xie S; Xu R; Yang H; Josey JA
    Cancer Res; 2016 Sep; 76(18):5491-500. PubMed ID: 27635045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
    Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
    Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cholecystokinin tetrapeptide amide metabolites in liver microsomes of human, Rhesus Monkey, Sprague-Dawley rat and CD1 mouse using ultra-high performance liquid chromatography coupled to high resolution mass spectrometer.
    Kong L; Berg FJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Oct; 1096():80-87. PubMed ID: 30149298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid detection and structural characterization of methysticin metabolites generated from rat and human liver microsomes and hepatocytes using ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry.
    Tuerxuntayi A; Tusun A; Tajiguli A
    Rapid Commun Mass Spectrom; 2021 Dec; 35(24):e9208. PubMed ID: 34606659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro metabolism of l-corydalmine, a potent analgesic drug, in human, cynomolgus monkey, beagle dog, rat and mouse liver microsomes.
    Tang X; Di X; Zhong Z; Xie Q; Chen Y; Wang F; Ling Z; Xu P; Zhao K; Wang Z; Liu L; Liu X
    J Pharm Biomed Anal; 2016 Sep; 128():98-105. PubMed ID: 27239758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of in vitro metabolites of TM-2, a potential antitumor drug, in rat, dog and human liver microsomes using liquid chromatography/tandem mass spectrometry.
    Men L; Zhao Y; Lin H; Yang M; Liu H; Tang X; Yu Z
    Rapid Commun Mass Spectrom; 2014 Oct; 28(20):2162-70. PubMed ID: 25178720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.